journal article·2024-12-31Open access

Nitrogen-doped carbon quantum dots as a novel treatment for black fungal bone infections (Mucormycosis): in vitro and in vivo study

Amany Belal, Atiah H. Almalki, Ahmed A. Farghali, Rehab Mahmoud, R. R. Atta, Abeer Enaiet Allah, Walid Hamdy Hassan, Sangmin Lee, Amna A. Kotp, Doaa Essam, Ahmed H. E. Hassan, Mohammed M. Ghoneim, Fatma I. Abo El-Ela, Abdalla Abdelwahab

Abstract

Most fungal bone and joint infections (arthritis) are caused by Mucormycosis (Mucor indicus). These infections may be difficult to treat and may lead to chronic bone disorders and disabilities, thus the use of new antifungal materials in bone disorders is vital, particularly in immunocompromised individuals, such as those who have contracted coronavirus disease 2019 (COVID-19). Herein, we reported for the first time the preparation of nitrogen-doped carbon quantum dots (N/CQDs) and a nitrogen-doped mesoporous carbon (N/MC) using a quick micro-wave preparation and hydrothermal approach. The structure and morphology were analysed using X-ray diffraction (XRD), field emission scanning electron microscopy (FESEM) and surface area analyser. Minimum inhibitory concentration (MIC), disc diffusion tests, minimum fungicidal concentration (MFC) and antifungal inhibitory percentages were measured to investigate the antifungal activity of N/CQDs and N/MC nanostructures. In addition to the in vivo antifungal activity in rats as determined by wound induction and infection, pathogen count and histological studies were also performed. According to in vitro and in vivo testing, both N/CQDs with small size and N/MC with porous structure had a significant antifungal impact on a variety of bone-infecting bacteria, including Mucor infection. In conclusion, the present investigation demonstrates that functional N/CQDs and N/MC are effective antifungal agents against a range of microbial pathogenic bone disorders in immunocompromised individuals, with stronger and superior fungicidal activity for N/CQDs than N/MC in vitro and in vivo studies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Antifungal resistance and susceptibility · Carbon and Quantum Dots Applications · Fungal Infections and Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif, Saudi Arabia

Addiction and Neuroscience Research Unit, College of Pharmacy, Taif University, Taif, Saudi Arabia

Materials Science and Nanotechnology Department, Faculty of Postgraduate Studies for Advanced Science (PSAS), Beni-Suef University, Beni-Suef, Egypt

Department of Chemistry, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt

Department of Chemistry, Faculty of Science, Damietta University, Damietta, Egypt

Mycology and Immunology Department, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef, Egypt

Department of Fundamental Pharmaceutical Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea

Department of Regulatory Science, Graduated School, Kyung Hee University, Seoul, Republic of Korea

Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

Medicinal Chemistry Laboratory, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea

Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah, Saudi Arabia

Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt

Department of Pharmacology, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef, Egypt

Faculty of Science, Galala University, Sokhna, Egypt

Funding

King Salman Center For Disability Research

References (64)

Show source-provided references
1. 10.1016/j.susmat.2022.e0039710.1016/j.susmat.2022.e00397 ↗
2. 10.3390/molecules2711361310.3390/molecules27113613 ↗
3. 10.3390/ijms23201252610.3390/ijms232012526 ↗
4. 10.1093/cid/ciab72610.1093/cid/ciab726 ↗
5. Chouhan AS, Parihar B, Rathod B, et al. Overuse of steroid drugs methylprednisolone and dexamethasone (oral) causes a diabetic patient to become infected with the black fungus in the corona virus. Sys Rev Pharm. 2021;12(11):630–634.
6. 10.1016/j.ijbiomac.2020.11.07510.1016/j.ijbiomac.2020.11.075 ↗
7. 10.1093/RB/RBAA01510.1093/RB/RBAA015 ↗
8. 10.1155/2013/53579610.1155/2013/535796 ↗
9. 10.3390/antibiotics1205079910.3390/antibiotics12050799 ↗
10. 10.1088/1361-6528/ac6df710.1088/1361-6528/ac6df7 ↗
11. 10.1016/j.ijhydene.2021.10.18610.1016/j.ijhydene.2021.10.186 ↗
12. 10.1016/j.jallcom.202210.1016/j.jallcom.2022 ↗
13. 10.1016/j.jare.2019.03.01110.1016/j.jare.2019.03.011 ↗
14. 10.1038/s41467-022-33474-810.1038/s41467-022-33474-8 ↗
15. 10.1021/acsnano.0c0523510.1021/acsnano.0c05235 ↗
16. 10.1002/smll.20210352810.1002/smll.202103528 ↗
17. 10.1016/j.fpsl.202210.1016/j.fpsl.2022 ↗
18. 10.1039/c8nr02647e10.1039/c8nr02647e ↗
19. 10.2147/IJN.S7833110.2147/IJN.S78331 ↗
20. 10.1016/j.jelechem.2022.11708310.1016/j.jelechem.2022.117083 ↗
21. 10.1002/(SICI)1099-1565(200005/06)11:3<137::AID-PCA514>3.0.CO;2-I10.1002/(SICI)1099-1565(200005/06)11:3<137::AID-PCA514>3.0.CO;2-I ↗
22. 10.3390/molecules1304079010.3390/molecules13040790 ↗
23. 10.1155/2014/37828010.1155/2014/378280 ↗
24. 10.1128/JCM.40200210.1128/JCM.402002 ↗
25. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement – M27-S3 Clinical and Laboratory Standards Institute – NCCLS; 2008.
26. 10.2174/092986703345771910.2174/0929867033457719 ↗
27. 10.1016/j.jep.2003.09.03910.1016/j.jep.2003.09.039 ↗
28. 10.5897/JMPR12.52510.5897/JMPR12.525 ↗
29. 10.1097/00005373-196811000-0000610.1097/00005373-196811000-00006 ↗
30. 10.3390/molecules1505318610.3390/molecules15053186 ↗
31. Merkelbach M, Kemp E, To R, et al. International committee of the red cross no 主観的健康感を中心とした在宅高齢者における 健康関連指標に関する共分散構造分析 title. VA J Int Law. 1979;15:1–50.
32. 10.1351/pac19855704060310.1351/pac198557040603 ↗
33. 10.1016/j.jpowsour.202210.1016/j.jpowsour.2022 ↗
34. 10.1016/j.jece.202010.1016/j.jece.2020 ↗
35. 10.1016/j.est.201910.1016/j.est.2019 ↗
36. 10.3390/nano1110252510.3390/nano11102525 ↗
37. 10.3390/nano1109224910.3390/nano11092249 ↗
38. 10.1093/mmy/myw13610.1093/mmy/myw136 ↗
39. 10.5194/jbji-8-202310.5194/jbji-8-2023 ↗
40. 10.1093/cid/cir86610.1093/cid/cir866 ↗
41. 10.1111/1469-0691.1256610.1111/1469-0691.12566 ↗
42. 10.1016/j.ijid.2017.07.00210.1016/j.ijid.2017.07.002 ↗
43. 10.1016/j.bjps.2008.04.04010.1016/j.bjps.2008.04.040 ↗
44. 10.1111/myc.1279810.1111/myc.12798 ↗
45. 10.1080/13102818.2022.214653310.1080/13102818.2022.2146533 ↗
46. 10.7164/antibiotics.4810.7164/antibiotics.48 ↗
47. 10.1055/s-2007-98156110.1055/s-2007-981561 ↗
48. CLSI reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard—second edition serving the world’s medical science community through voluntary consensus; Wayne Pennsylvania USA: Clinical and Laboratory Standards Institute 2008.
49. Rex JH Alexander BD Andes D et al. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. 3rd ed. Wayne Pennsylvania USA: Clinical and Laboratory Standards Institute; 2008.
50. 10.1016/j.ejmech.2005.06.00910.1016/j.ejmech.2005.06.009 ↗
51. 10.1016/j.bjm.2016.12.00810.1016/j.bjm.2016.12.008 ↗
52. 10.1016/j.micpath.2020.10417810.1016/j.micpath.2020.104178 ↗
53. 10.2217/nnm.10.3210.2217/nnm.10.32 ↗
54. 10.1517/14656566.2015.102178010.1517/14656566.2015.1021780 ↗
55. 10.12968/jowc.2013.2210.12968/jowc.2013.22 ↗
56. 10.1016/S0039-6109(05)70572-710.1016/S0039-6109(05)70572-7 ↗
57. 10.1016/S1015-9584(09)60061-010.1016/S1015-9584(09)60061-0 ↗
58. 10.1111/j.1472-765X.2007.02157.x10.1111/j.1472-765X.2007.02157.x ↗
59. 10.1021/acsnano.7b0102310.1021/acsnano.7b01023 ↗
60. 10.1016/j.jmrt.2022.05.17510.1016/j.jmrt.2022.05.175 ↗
61. 10.1088/1757-899X/1046/1/01202510.1088/1757-899X/1046/1/012025 ↗
62. 10.1039/d0nr03134h10.1039/d0nr03134h ↗
63. 10.1016/j.reactfunctpolym.2016.03.00410.1016/j.reactfunctpolym.2016.03.004 ↗
64. 10.1016/S1003-6326(21)65767-910.1016/S1003-6326(21)65767-9 ↗